Taking RNA epigenetics by Storm

Storm Therapeutics Ltd. is the first company to come out of the budding field of RNA epigenetics, and is targeting RNA-modifying enzymes for cancer.

CEO Keith Blundy told BioCentury RNA-modifying enzymes fit into the landscape of epigenetic targets because, like DNA-modifying enzymes, they alter gene expression without changing the genetic code.

"It's the same paradigm as DNA and histone modification enzymes that have